Cancer Institute of New Jersey (CINJ), Melanoma & Soft Tissue Oncology

Research Output 2003 2019

Filter
Article
2019
1 Citation (Scopus)

A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors

Stein, M., Goodin, S., Gounder, M., Gibbon, D., Moss, R., Portal, D., Lindquist, D., Zhao, Y., Takebe, N., Tan, A., Aisner, J., Lin, H., Ready, N. & Mehnert, J., Jan 1 2019, (Accepted/In press) In : Investigational New Drugs.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Neoplasms
Area Under Curve
Prostate

A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors

Mehnert, J., Kaveney, A. D., Malhotra, J., Spencer, K., Portal, D., Goodin, S., Tan, A. R., Aisner, J., Moss, R. A., Lin, H., Bertino, J., Gibbon, D., Doyle, L. A., White, E. & Stein, M., Jan 1 2019, (Accepted/In press) In : Cancer chemotherapy and pharmacology.

Research output: Contribution to journalArticle

Hydroxychloroquine
Tumors
Neoplasms
Exanthema
Fatigue
5 Citations (Scopus)

Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial

Keilholz, U., Mehnert, J., Bauer, S., Bourgeois, H., Patel, M. R., Gravenor, D., Nemunaitis, J. J., Taylor, M. H., Wyrwicz, L., Lee, K. W., Kasturi, V., Chin, K., Von Heydebreck, A. & Gulley, J. L., Jan 16 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 12.

Research output: Contribution to journalArticle

Melanoma
Neoplasms
Therapeutics
Disease-Free Survival
Survival
1 Citation (Scopus)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma

Andtbacka, R. H. I., Amatruda, T., Nemunaitis, J., Zager, J. S., Walker, J., Chesney, J. A., Liu, K., Hsu, C. P., Pickett, C. A. & Mehnert, J., Sep 1 2019, In : EBioMedicine. 47, p. 89-97 9 p.

Research output: Contribution to journalArticle

Open Access
Oncolytic Viruses
Viruses
Melanoma
Occlusive Dressings
Blood

Clinical characterization of colitis arising from anti-PD-1 based therapy

Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R., Silk, A., Zhou, A., Compton, M. L., Al-Rohil, R. N., Lee, S., Voorhees, A. L., Ha, L., McKee, S., Norrell, J. T., Mehnert, J., Puzanov, I., Sosman, J. A., Chandra, S. & 5 others, Gibney, G. T., Rapisuwon, S., Eroglu, Z., Sullivan, R. & Johnson, D. B., Jan 2 2019, In : OncoImmunology. 8, 1, e1524695.

Research output: Contribution to journalArticle

Colitis
Steroids
Therapeutics
Prednisone
Melanoma
4 Citations (Scopus)

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma

D’Angelo, S. P., Hunger, M., Brohl, A. S., Nghiem, P., Bhatia, S., Hamid, O., Mehnert, J., Terheyden, P., Shih, K. C., Brownell, I., Lebbé, C., Lewis, K. D., Linette, G. P., Milella, M., Schlichting, M., Hennessy, M. H. & Bharmal, M., Apr 2 2019, In : Cancer Immunology, Immunotherapy. 68, 4, p. 609-618 10 p.

Research output: Contribution to journalArticle

Merkel Cell Carcinoma
Survival
Confidence Intervals
Therapeutics
Proportional Hazards Models
3 Citations (Scopus)

Interferon Lambda: Toward a Dual Role in Cancer

Lasfar, A., Zloza, A., Silk, A., Lee, L. & Cohen-Solal, K. A., Jan 1 2019, In : Journal of Interferon and Cytokine Research. 39, 1, p. 22-29 8 p.

Research output: Contribution to journalArticle

Interferons
Neoplasms
Inflammation
Janus Kinases
Transducers

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma

Chesney, J., Puzanov, I., Collichio, F., Milhem, M. M., Hauschild, A., Chen, L., Sharma, A., Garbe, C., Singh, P. & Mehnert, J., Aug 27 2019, In : British Journal of Cancer. 121, 5, p. 417-420 4 p.

Research output: Contribution to journalArticle

Melanoma
Tumor Burden
ipilimumab
Therapeutics
11 Citations (Scopus)

Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028

Varga, A., Piha-Paul, S., Ott, P. A., Mehnert, J. M., Berton-Rigaud, D., Morosky, A., Yang, P., Ruman, J. & Matei, D., Feb 2019, In : Gynecologic Oncology. 152, 2, p. 243-250 8 p.

Research output: Contribution to journalArticle

Ovarian Neoplasms
Ligands
Therapeutics
Research Personnel
Safety

Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma

Portal, D. E., Weiss, R. E., Wojtowicz, M., Mansour, A., Monken, C., Mehnert, J. M., Aisner, J. A., Kane, M., Nishioka, J., Aisner, S., Peters, S., Stein, M. N., Kim, I. Y., Mayer, T. M., Shih, W., Gulley, J., Streicher, H., Singer, E. A. & Lattime, E. C., Jan 1 2019, In : Cancer gene therapy.

Research output: Contribution to journalArticle

Fowlpox
Granulocyte-Macrophage Colony-Stimulating Factor
Urinary Bladder
Urinary Bladder Neoplasms
Carcinoma
1 Citation (Scopus)

Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: A multicenter, retrospective case series

Lopiccolo, J., Schollenberger, M. D., Dakhil, S., Rosner, S., Ali, O., Sharfman, W. H., Silk, A. W., Bhatia, S. & Lipson, E. J., Jul 8 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 170.

Research output: Contribution to journalArticle

Open Access
Merkel Cell Carcinoma
Therapeutics
Neoplasms
Blocking Antibodies
Multicenter Studies
4 Citations (Scopus)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer

Mehnert, J. M., Varga, A., Brose, M. S., Aggarwal, R. R., Lin, C. C., Prawira, A., De Braud, F., Tamura, K., Doi, T., Piha-Paul, S. A., Gilbert, J., Saraf, S., Thanigaimani, P., Cheng, J. D. & Keam, B., Mar 4 2019, In : BMC cancer. 19, 1, 196.

Research output: Contribution to journalArticle

Ligands
Safety
Antibodies
Thyroid Neoplasms
Confidence Intervals
39 Citations (Scopus)

T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028

Ott, P. A., Bang, Y. J., Piha-Paul, S. A., Abdul Razak, A. R., Bennouna, J., Soria, J. C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J., Lopez, J., Doi, T., van Brummelen, E. M. J., Cristescu, R., Yang, P., Emancipator, K., Stein, K., Ayers, M., Joe, A. K. & Lunceford, J. K., Feb 1 2019, In : Journal of Clinical Oncology. 37, 4, p. 318-327 10 p.

Research output: Contribution to journalArticle

Tumor Burden
Transcriptome
Ligands
Neoplasms
Disease-Free Survival
3 Citations (Scopus)

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Buchbinder, E. I., Dutcher, J. P., Daniels, G. A., Curti, B. D., Patel, S. P., Holtan, S. G., Miletello, G. P., Fishman, M. N., Gonzalez, R., Clark, J. I., Richart, J. M., Lao, C. D., Tykodi, S. S., Silk, A. & McDermott, D. F., Feb 18 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 49.

Research output: Contribution to journalArticle

Open Access
Renal Cell Carcinoma
Interleukin-2
Melanoma
Therapeutics
Pneumonia
2018
13 Citations (Scopus)

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: Version 2.0

Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L., Gajewski, T. F., Gastman, B., Lawson, D. H., Lutzky, J., McDermott, D. F., Margolin, K. A., Mehnert, J. M., Pavlick, A. C., Richards, J. M., Rubin, K. M., Sharfman, W., Silverstein, S., Slingluff, C. L. & 8 others, Sondak, V. K., Tarhini, A. A., Thompson, J. A., Urba, W. J., White, R. L., Whitman, E. D., Hodi, F. S. & Kaufman, H. L., May 30 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 44.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Consensus
Skin
Advisory Committees
2 Citations (Scopus)

A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors

Mehnert, J., Edelman, G., Stein, M., Camisa, H., Lager, J., Dedieu, J. F., Ghuysen, A. F., Sharma, J., Liu, L. & LoRusso, P. M., Feb 1 2018, In : Investigational New Drugs. 36, 1, p. 36-44 9 p.

Research output: Contribution to journalArticle

1-Phosphatidylinositol 4-Kinase
Tablets
Pharmacokinetics
Safety
Neoplasms
4 Citations (Scopus)

A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma

Mehnert, J. M., Silk, A. W., Lee, J. H., Dudek, L., Jeong, B. S., Li, J., Schenkel, J. M., Sadimin, E., Kane, M., Lin, H., Shih, W. J., Zloza, A., Chen, S. & Goydos, J. S., Jul 2018, In : Pigment Cell and Melanoma Research. 31, 4, p. 534-540 7 p.

Research output: Contribution to journalArticle

Riluzole
Tumors
Melanoma
Pharmacokinetics
Down-Regulation
27 Citations (Scopus)

Immune activation and benefit from avelumab in EBV-positive gastric cancer

Panda, A., Mehnert, J., Hirshfield, K., Riedlinger, G., Damare, S., Saunders, T., Kane, M., Sokol, L., Stein, M., Poplin, E., Rodriguez-Rodriguez, L., Silk, A., Aisner, J., Chan, N., Malhotra, J., Frankel, M., Kaufman, H. L., Ali, S., Ross, J. S., White, E. P. & 2 others, Bhanot, G. & Ganesan, S., Mar 1 2018, In : Journal of the National Cancer Institute. 110, 3, p. 316-320 5 p.

Research output: Contribution to journalArticle

Human Herpesvirus 4
Stomach Neoplasms
Microsatellite Repeats
Neoplasms
Mutation
1 Citation (Scopus)

Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma

Hurwitz, M. E., Markowski, P., Yao, X., Deshpande, H., Patel, J., Mortazavi, A., Donadio, A., Stein, M., Kelly, W. K., Petrylak, D. P. & Mehnert, J., Dec 1 2018, In : Clinical Genitourinary Cancer. 16, 6, p. 437-444.e6

Research output: Contribution to journalArticle

gemcitabine
Transitional Cell Carcinoma
Carboplatin
Confidence Intervals
Protein-Tyrosine Kinases
1 Citation (Scopus)

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)

Ascierto, P. A., Puzanov, I., Agarwala, S. S., Bifulco, C., Botti, G., Caracò, C., Ciliberto, G., Davies, M. A., Dummer, R., Ferrone, S., Gajewski, T. F., Garbe, C., Luke, J. J., Marincola, F. M., Masucci, G., Mehnert, J. M., Mozzillo, N., Palmieri, G., Postow, M. A., Schoenberger, S. P. & 2 others, Wang, E. & Thurin, M., Jul 21 2018, In : Journal of translational medicine. 16, 1, 207.

Research output: Contribution to journalArticle

Italy
Tumors
Melanoma
Proto-Oncogene Proteins B-raf
T-cells
2 Citations (Scopus)

Phase IB results of the rational combination of selumetinib and cyclosporin A in advanced solid tumors with an expansion cohort in metastatic colorectal cancer

Krishnamurthy, A., Dasari, A., Noonan, A. M., Mehnert, J. M., Lockhart, A. C., Leong, S., Capasso, A., Stein, M. N., Sanoff, H. K., Lee, J. J., Hansen, A., Malhotra, U., Rippke, S., Gustafson, D. L., Pitts, T. M., Ellison, K., Davis, S. L., Messersmith, W. A., Eckhardt, S. G. & Lieu, C. H., Sep 15 2018, In : Cancer Research. 78, 18, p. 5398-5407 10 p.

Research output: Contribution to journalArticle

Cyclosporine
Colorectal Neoplasms
Wnt Signaling Pathway
Neoplasms
oxaliplatin
10 Citations (Scopus)

Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors

Margolin, K., Morishima, C., Velcheti, V., Miller, J. S., Lee, S. M., Silk, A. W., Holtan, S. G., Lacroix, A. M., Fling, S. P., Kaiser, J. C., Egan, J. O., Jones, M., Rhode, P. R., Rock, A. D., Cheever, M. A., Wong, H. C. & Ernstoff, M. S., Nov 15 2018, In : Clinical Cancer Research. 24, 22, p. 5552-5561 10 p.

Research output: Contribution to journalArticle

Interleukin-15
Neoplasms
Natural Killer Cells
Melanoma
Lymphocytes
23 Citations (Scopus)

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

Kelly, K., Infante, J. R., Taylor, M. H., Patel, M. R., Wong, D. J., Iannotti, N., Mehnert, J. M., Loos, A. H., Koch, H., Speit, I. & Gulley, J. L., May 1 2018, In : Cancer. 124, 9, p. 2010-2017 8 p.

Research output: Contribution to journalArticle

Clinical Trials
Safety
Neoplasms
avelumab
CD274 Antigen
2017
18 Citations (Scopus)

BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in BRAFV600E mutant melanoma

Kulkarni, A., Al-Hraishawi, H., Simhadri, S., Hirshfield, K. M., Chen, S., Pine, S., Jeyamohan, C., Sokol, L., Ali, S., Teo, M. L., White, E., Rodriguez-Rodriguez, L., Mehnert, J. M. & Ganesan, S., Sep 15 2017, In : Clinical Cancer Research. 23, 18, p. 5631-5638 8 p.

Research output: Contribution to journalArticle

Melanoma
Gene Fusion
Mitogen-Activated Protein Kinase Kinases
Mutation
PLX4032
32 Citations (Scopus)

First-in-human clinical trial of oral ONC201 in patients with refractory solid tumors

Stein, M., Bertino, J., Kaufman, H. L., Mayer, T., Moss, R., Silk, A., Chan, N., Malhotra, J., Rodriguez-Rust, L., Aisner, J., Aiken, R., Haffty, B., DiPaola, R. S., Saunders, T., Zloza, A., Damare, S., Beckett, Y., Yu, B., Najmi, S., Gabel, C. & 7 others, Dickerson, S., Zheng, L., El-Deiry, W. S., Allen, J. E., Stogniew, M., Oster, W. & Mehnert, J., Aug 1 2017, In : Clinical Cancer Research. 23, 15, p. 4163-4169 7 p.

Research output: Contribution to journalArticle

Clinical Trials
Neoplasms
Pharmacokinetics
Keratin-18
Endometrial Neoplasms
15 Citations (Scopus)

Immuno-oncology clinical trial design: Limitations, challenges, and opportunities

Baik, C. S., Rubin, E. H., Forde, P. M., Mehnert, J. M., Collyar, D., Butler, M. O., Dixon, E. L. & Chow, L. Q. M., Sep 1 2017, In : Clinical Cancer Research. 23, 17, p. 4992-5002 11 p.

Research output: Contribution to journalArticle

Clinical Trials
Neoplasms
Therapeutics
Safety
Virus Diseases
241 Citations (Scopus)

Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Nov 21 2017, In : Journal for ImmunoTherapy of Cancer. 5, 1, 95.

Research output: Contribution to journalArticle

Immunotherapy
Neoplasms
Therapeutic Uses
Therapeutics
Nervous System
123 Citations (Scopus)

Pembrolizumab in patients with extensive-stage small-cell lung cancer: Results from the phase Ib KEYNOTE-028 study

Ott, P. A., Elez, E., Hiret, S., Kim, D. W., Morosky, A., Saraf, S., Piperdi, B. & Mehnert, J., Dec 1 2017, In : Journal of Clinical Oncology. 35, 34, p. 3823-3829 7 p.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Safety
Asthenia
Ligands
pembrolizumab
2 Citations (Scopus)
Radiotherapy
Neoplasm Metastasis
Therapeutics
92 Citations (Scopus)

Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: Results from the KEYNOTE-028 study

Ott, P. A., Bang, Y. J., Berton-Rigaud, D., Elez, E., Pishvaian, M. J., Rugo, H. S., Puzanov, I., Mehnert, J., Aung, K. L., Lopez, J., Carrigan, M., Saraf, S., Chen, M. & Soria, J. C., Aug 1 2017, In : Journal of Clinical Oncology. 35, 22, p. 2535-2541 7 p.

Research output: Contribution to journalArticle

Endometrial Neoplasms
Ligands
Safety
pembrolizumab
Therapeutics
68 Citations (Scopus)

Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study

Hsu, C., Lee, S. H., Ejadi, S., Even, C., Cohen, R. B., Le Tourneau, C., Mehnert, J., Algazi, A., Van Brummelen, E. M. J., Saraf, S., Thanigaimani, P., Cheng, J. D. & Hansen, A. R., Dec 20 2017, In : Journal of Clinical Oncology. 35, 36, p. 4050-4056 7 p.

Research output: Contribution to journalArticle

Ligands
Safety
Drug-Related Side Effects and Adverse Reactions
Nasopharyngeal carcinoma
pembrolizumab
24 Citations (Scopus)

The challenge for development of valuable immuno-oncology biomarkers

Mehnert, J., Monjazeb, A. M., Beerthuijzen, J. M. T., Collyar, D., Rubinstein, L. & Harris, L. N., Sep 1 2017, In : Clinical Cancer Research. 23, 17, p. 4970-4979 10 p.

Research output: Contribution to journalArticle

Biomarkers
Tumor Microenvironment
Immunotherapy
Tumor-Infiltrating Lymphocytes
Tumor Burden
2016
14 Citations (Scopus)

A Phase II Study of AT-101 to Overcome Bcl-2-Mediated Resistance to Androgen Deprivation Therapy in Patients with Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer

Stein, M. N., Hussain, M., Stadler, W. M., Liu, G., Tereshchenko, I. V., Goodin, S., Jeyamohan, C., Kaufman, H. L., Mehnert, J. & Dipaola, R. S., Feb 1 2016, In : Clinical Genitourinary Cancer. 14, 1, p. 22-27 6 p.

Research output: Contribution to journalArticle

Castration
Androgens
Prostatic Neoplasms
Prostate-Specific Antigen
Therapeutics
22 Citations (Scopus)

Biomarkers for Immunotherapy: Current Developments and Challenges

Spencer, K. R., Wang, J., Silk, A., Ganesan, S., Kaufman, H. L. & Mehnert, J., Jan 1 2016, In : American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting. 35, p. e493-e503

Research output: Contribution to journalArticle

Immunotherapy
Biomarkers
Tumor Microenvironment
Neoplasms
Tumor-Infiltrating Lymphocytes
21 Citations (Scopus)

Clinical actionability of comprehensive genomic profiling for management of rare or refractory cancers

Hirshfield, K., Tolkunov, D., Zhong, H., Ali, S. M., Stein, M., Murphy, S., Vig, H., Vazquez, A., Glod, J., Moss, R. A., Belyi, V., Chan, C., Chen, S., Goodell, L., Foran, D., Yelensky, R., Palma, N. A., Sun, J. X., Miller, V. A., Stephens, P. J. & 10 others, Ross, J. S., Kaufman, H., Poplin, E., Mehnert, J., Tan, A. R., Bertino, J., Aisner, J., DiPaola, R. S., Rodriguez-Rodriguez, L. & Ganesan, S., Nov 1 2016, In : Oncologist. 21, 11, p. 1315-1325 11 p.

Research output: Contribution to journalArticle

Neoplasms
Histology
Proto-Oncogene Proteins c-akt
Genetic Testing
Receptor Protein-Tyrosine Kinases
11 Citations (Scopus)

Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015

Ascierto, P. A., Agarwala, S., Botti, G., Cesano, A., Ciliberto, G., Davies, M. A., Demaria, S., Dummer, R., Eggermont, A. M., Ferrone, S., Fu, Y. X., Gajewski, T. F., Garbe, C., Huber, V., Khleif, S., Krauthammer, M., Lo, R. S., Masucci, G., Palmieri, G., Postow, M. & 16 others, Puzanov, I., Silk, A., Spranger, S., Stroncek, D. F., Tarhini, A., Taube, J. M., Testori, A., Wang, E., Wargo, J. A., Yee, C., Zarour, H., Zitvogel, L., Fox, B. A., Mozzillo, N., Marincola, F. M. & Thurin, M., Nov 15 2016, In : Journal of translational medicine. 14, 1, 313.

Research output: Contribution to journalArticle

Biomarkers
Melanoma
Immunotherapy
Tumors
CTLA-4 Antigen
30 Citations (Scopus)

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma

Schadendorf, D., Dummer, R., Hauschild, A., Robert, C., Hamid, O., Daud, A., van den Eertwegh, A., Cranmer, L., O'Day, S., Puzanov, I., Schachter, J., Blank, C., Salama, A., Loquai, C., Mehnert, J. M., Hille, D., Ebbinghaus, S., Kang, S. P., Zhou, W. & Ribas, A., Nov 1 2016, In : European Journal of Cancer. 67, p. 46-54 9 p.

Research output: Contribution to journalArticle

Melanoma
Quality of Life
Drug Therapy
Health Status
ipilimumab
113 Citations (Scopus)

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

Mehnert, J., Panda, A., Zhong, H., Hirshfield, K., Damare, S., Lane, K., Sokol, L., Stein, M., Rodriguez-Rodriquez, L., Kaufman, H. L., Ali, S., Ross, J. S., Pavlick, D. C., Bhanot, G., White, E., DiPaola, R. S., Lovell, A., Cheng, J. & Ganesan, S., Jun 1 2016, In : Journal of Clinical Investigation. 126, 6, p. 2334-2340 7 p.

Research output: Contribution to journalArticle

Endometrial Neoplasms
Mutation
Programmed Cell Death 1 Receptor
Neoplasms
DNA Polymerase II
83 Citations (Scopus)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

Rehman, H., Silk, A. W., Kane, M. P. & Kaufman, H. L., Sep 20 2016, In : Journal for ImmunoTherapy of Cancer. 4, 1, 53.

Research output: Contribution to journalArticle

Melanoma
Oncolytic Viruses
Therapeutics
Drug Compounding
Explosions
220 Citations (Scopus)

Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders

Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., Mudigonda, T., Spencer, K., Bender, C., Lee, J., Kaufman, H. L., Menzies, A. M., Hassel, J. C., Mehnert, J., Sosman, J. A., Long, G. V. & 1 others, Clark, J. I., Feb 1 2016, In : JAMA Oncology. 2, 2, p. 234-240 7 p.

Research output: Contribution to journalArticle

Preexisting Condition Coverage
Melanoma
Autoimmune Diseases
Therapeutics
Safety
2015
71 Citations (Scopus)

Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma

Xie, X., Koh, J. Y., Price, S., White, E. & Mehnert, J. M., Apr 1 2015, In : Cancer Discovery. 5, 4, p. 410-423 14 p.

Research output: Contribution to journalArticle

Autophagy
Melanoma
Growth
Essential Genes
Neoplasms
7 Citations (Scopus)

Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors

Higano, C. S., Berlin, J., Gordon, M., Lorusso, P., Tang, S., Dontabhaktuni, A., Schwartz, J. D., Cosaert, J. & Mehnert, J., Apr 1 2015, In : Investigational New Drugs. 33, 2, p. 450-462 13 p.

Research output: Contribution to journalArticle

IGF Type 1 Receptor
Pharmacokinetics
Safety
Neoplasms
Maximum Tolerated Dose
2014
22 Citations (Scopus)

Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression

Wen, Y., Li, J., Koo, J., Shin, S. S., Lin, Y., Jeong, B. S., Mehnert, J. M., Chen, S., Cohen-Sola, K. A. & Goydos, J. S., Jan 5 2014, In : Cancer Research. 74, 9, p. 2499-2509 11 p.

Research output: Contribution to journalArticle

Glutamate Receptors
Melanoma
Riluzole
Phosphatidylinositol 3-Kinases
Blood Vessels
22 Citations (Scopus)

Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: A multicenter, retrospective case series

Ravi, S., Spencer, K., Ruisi, M., Ibrahim, N., Luke, J. J., Thompson, J. A., Shirai, K., Lawson, D., Bartell, H., Kudchadkar, R., Gunter, N. T., Mehnert, J. M. & Lipson, E. J., Oct 14 2014, In : Journal for ImmunoTherapy of Cancer. 2, 1, 33.

Research output: Contribution to journalArticle

Hepatitis C
Hepatitis B
Melanoma
Infection
CTLA-4 Antigen
8 Citations (Scopus)

Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor

Teh, J. L. F., Shah, R., Shin, S. S., Wen, Y., Mehnert, J., Goydos, J. & Chen, S., Jan 1 2014, In : Pigment Cell and Melanoma Research. 27, 4, p. 621-629 9 p.

Research output: Contribution to journalArticle

Somatomedin Receptors
Melanocytes
Somatomedins
Transcriptional Activation
Tumors
50 Citations (Scopus)

Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies

Salgia, R., Patel, P., Bothos, J., Yu, W., Eppler, S., Hegde, P., Bai, S., Kaur, S., Nijem, I., Catenacci, D. V. T., Peterson, A., Ratain, M. J., Polite, B., Mehnert, J. M. & Moss, R. A., Jan 1 2014, In : Clinical Cancer Research. 20, 6, p. 1666-1675 10 p.

Research output: Contribution to journalArticle

Pharmacokinetics
Neoplasms
Antibodies
Proto-Oncogene Proteins c-met
Safety
2013
89 Citations (Scopus)

Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma

Xie, X., White, E. P. & Mehnert, J. M., Jan 30 2013, In : PloS one. 8, 1, e55096.

Research output: Contribution to journalArticle

autophagy
Autophagy
Cell death
melanoma
cell death
13 Citations (Scopus)

Ipilimumab administration in patients with advanced melanoma and hepatitis B and C

Sharma, A., Thompson, J. A., Repaka, A. & Mehnert, J., Jul 20 2013, In : Journal of Clinical Oncology. 31, 21

Research output: Contribution to journalArticle

Hepatitis C
Hepatitis B
Melanoma
Monoclonal Antibodies
ipilimumab
149 Citations (Scopus)

Ipilimumab and radiation therapy for melanoma brain metastases

Silk, A. W., Bassetti, M. F., West, B. T., Tsien, C. I. & Lao, C. D., Dec 2013, In : Cancer Medicine. 2, 6, p. 899-906 8 p.

Research output: Contribution to journalArticle

Melanoma
Radiotherapy
Neoplasm Metastasis
Brain
Survival
2012
35 Citations (Scopus)

Driver mutations in melanoma: Lessons learned from bench-to-bedside studies

Mehnert, J. & Kluger, H. M., Oct 1 2012, In : Current oncology reports. 14, 5, p. 449-457 9 p.

Research output: Contribution to journalArticle

Melanoma
Mutation
Melanocytes
Molecular Biology
Skin